Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer

28 Aug 2019

Abstract excerpt

Abstract High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy, but most patients relapse with chemotherapy-resistant disease. To systematically identify genes modulating chemotherapy response, we performed pooled functional genomic screens in HGSOC cell lines treated with cisplatin, paclitaxel, or cisplatin plus paclitaxel. Genes in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to CRISPR and Genetic Engineering
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31462500
DOI: 10.1158/1541-7786.mcr-18-1243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerPMID 31462500Read ↗

Integrated analysis of scRNA-seq and bulk RNA-seq identifies FBXO2 as a candidate biomarker associated with chemoresistance in HGSOCSemantic proximity Read ↗

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity Read ↗

Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatmentSemantic proximity Read ↗

Suppression of <i>ABHD2</i>, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancerSemantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient SurvivalSemantic proximity Read ↗

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patientsSemantic proximity Read ↗

Novel regulatory and transcriptional networks associated with resistance to platinum-based chemotherapy in ovarian cancerSemantic proximity Read ↗

Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene TargetsSemantic proximity Read ↗

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.Semantic proximity Read ↗

Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS AmplificationSemantic proximity Read ↗

Chemoresistance in human ovarian cancer: the role of apoptotic regulatorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.